Ustekinumab for treating active psoriatic arthritis

  • Technology appraisal guidance
  • TA340
  • Published: 
  • Last updated: 

Review decision - September 2016

Review of NICE Technology Appraisal Guidance No.199; Etanercept, Infliximab, and Adalimumab for the treatment of psoriatic arthritis, No.220; Golimumab for the treatment of psoriatic arthritis, and No.340; Ustekinumab for treating active psoriatic arthritis

Decision to move the existing guidance to the static list – September 2016

The Institute was proposing that TA199, TA220 and TA340 should all be moved to the static list.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA199, TA220 and TA340 will be moved to the static list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

Review decision paper

This page was last updated: